Charles River Laboratories (CRL) Income Statement

An income statement shows a company's revenue, expenses, and profit over a reporting period.

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally.

Total Revenue Chart for Charles River Laboratories

Charles River Laboratories (CRL) revenue for FY2025 was USD 4.0B, a -0.9% change from FY2024. Charles River Laboratories's revenue grew from USD 193.3M in 1998 to USD 4.0B in 2025 (1977.3% over 27 years). Earnings per share grew from USD 0.56 in 2000 to USD -2.91 in 2025 (-622.4%). Revenue compound annual growth rate: 5-year CAGR of 6.5%, 10-year CAGR of 11.4%, 20-year CAGR of 6.6%.

The most recent 8 years are real; the rest is blurred as a preview. Sign up free to unlock every line item, quarterly data, and the real full history. Free account: 8 years of history for 10 flagship companies. Premium: full history for 500+ companies. Premium is €10.00/month. See pricing.